Pfizer looks to expand ADC use after positive bladder cancer data
Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify for chemotherapy.
Previous Post
Another explanation for canceled mRNA contracts
Next Post
How Wireless Handheld Ultrasound Devices Are Changing Point-of-Care Diagnostics
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago